Image
illustration
Venture Capital Acquisitions & Partnerships

MABLINK and Emergence Therapeutics enter into a Licensing Agreement

Thursday 21 October, 2021
Body

Under the terms of the agreement, Emergence Therapeutics will use a PSARlink drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers. 

Content